argenx is a clinical-stage biotechnology company developing differentiated therapies for the treatment of severe autoimmune diseases and cancer. Co. is developing its main product candidate, efgartigimod, for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris and chronic demyelinating polyneuropathy, all of which are severe autoimmune diseases associated with high levels of circulating pathogenic immunoglobulin G antibodies for which there are few biologic treatments and a severe unmet medical need exists. Co. is also developing cusatuzumab in hematological cancer indications, acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.